Skip to main content

Research Findings

Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026

Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026

New York – September 30, 2026 -- Direct-to-patient healthcare company Ro presented the first real-world evidence on Novo Nordisk's oral Wegovy pill at the EASD2026 meeting in Milan on September 30, based on outcomes from patients on its platform who switched from an injectable GLP-1.

Ro's platform generates first clinical data on Wegovy pill switch patients

The short oral session study, co-authored by Ro clinical advisors Dr. Beverly Tchang and Dr. Louis Aronne, tracked patients with overweight or obesity who transitioned from an injectable GLP-1 and remained persistent with the Wegovy pill for three months on Ro's platform.

DCD Heart Transplants Expand in US Without Worse Outcomes, Study Finds

DCD Heart Transplants Expand in US Without Worse Outcomes, Study Finds

Washington – September 15, 2026 -- Donation after circulatory death (DCD) heart transplantation expanded rapidly across the United States between 2019 and 2024 without any measurable decline in early clinical outcomes, according to research published in the September 2026 issue of the Journal of Cardiac Failure (JCF).

Registry data on 1,489 patients show no rise in graft failure or mortality

Investigators analyzed U.S. registry data covering 1,489 adult DCD heart transplant recipients, comparing the early adoption period of 2019-2021 with the national expansion period of 2022-2024. The analysis found no significant differences in one-year graft failure, mortality, need for renal replacement therapy, re-transplantation or hospital length of stay between the two periods. Outcomes remained consistent even among higher-risk recipients, as DCD transplantation spread to a growing number of transplant centers nationwide.

Subscribe to Research Findings